1. Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature
- Author
-
Natsuki, Ishikawa, Kenya, Kamimura, Saori, Endo, Soichi, Ishii, Kazuya, Ogawa, Norihiro, Sakai, Hiroyuki, Abe, Masayoshi, Ko, Osamu, Shibata, Youhei, Koseki, Junji, Yokoyama, Akira, Sakamaki, and Shuji, Terai
- Subjects
Male ,Bevacizumab ,Carcinoma, Hepatocellular ,Liver Neoplasms ,Adrenal Glands ,Adrenal Gland Neoplasms ,Internal Medicine ,Humans ,General Medicine ,Middle Aged ,Sorafenib - Abstract
Regarding the prognosis of cases with advanced-stage hepatocellular carcinoma (HCC), a recent clinical study showed that the immune checkpoint inhibitors atezolizumab plus bevacizumab have superior efficacy to sorafenib. However, only a few reports have focused on their effects on extrahepatic metastases. We herein report a case of HCC in a 59-year-old man with intrahepatic lesions treated successfully by hepatic arterial chemoembolization, radiotherapy, and sorafenib; the extrahepatic lesion in the adrenal gland was treated by atezolizumab plus bevacizumab. The patient showed a tumor-free condition for one year. We have summarized the clinical course and reviewed the literature to underscore the efficacy of atezolizumab plus bevacizumab for treating extrahepatic lesions of HCC.
- Published
- 2022